N. Anthony Coles
2019 - Cerevel Therapeutics Holdings
In 2019, N. Anthony Coles earned a total compensation of $10.7M as Chairperson and Chief Executive Officer at Cerevel Therapeutics Holdings.
Compensation breakdown
| Non-Equity Incentive Plan | $229,212 |
|---|---|
| Option Awards | $9,817,097 |
| Salary | $398,630 |
| Other | $291,000 |
| Total | $10,735,939 |
Coles received $9.8M in option awards, accounting for 91% of the total pay in 2019.
Coles also received $229.2K in non-equity incentive plan, $398.6K in salary and $291K in other compensation.
Rankings
In 2019, N. Anthony Coles' compensation ranked 656th out of 13,971 executives tracked by ExecPay. In other words, Coles earned more than 95.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 656 out of 13,971 | 95th |
Division Manufacturing | 230 out of 5,701 | 96th |
Major group Chemicals And Allied Products | 61 out of 2,200 | 97th |
Industry group Drugs | 51 out of 1,886 | 97th |
Industry Pharmaceutical Preparations | 42 out of 1,398 | 97th |
Source: SEC filing on April 28, 2021.
Coles' colleagues
We found two more compensation records of executives who worked with N. Anthony Coles at Cerevel Therapeutics Holdings in 2019.
News
Cerevel Therapeutics Holdings CEO N Coles' 2021 pay jumps 990% to $8.1M
April 28, 2022
KINETA CEO Richard MDPhD receives $4.5M in 2021
April 25, 2022
Cerevel Therapeutics Holdings Chief Corporate Affairs Officer Kathleen MA receives $3.7M in 2020
April 28, 2021
KINETA CEO Meenu Chhabra's 2020 pay jumps 65% to $3.3M
April 22, 2021